Heartflow, Inc. [●] Shares of Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • August 1st, 2025 • Heartflow, Inc. • Surgical & medical instruments & apparatus • New York
Heartflow, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC (“J.P. Morgan”), Morgan Stanley & Co. LLC (“Morgan Stanley”) and Piper Sandler & Co. (“Piper”) are acting as Representatives (the “Representatives”), an aggregate of [●] shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
DYADIC INTERNATIONAL, INC. 6,052,000 Shares of Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • August 1st, 2025 • Dyadic International Inc • Biological products, (no disgnostic substances) • New York
Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions, a Delaware corporation (the “Company”), proposes to issue and sell to Craig-Hallum Capital Group LLC, in its capacity as underwriter (the “Underwriter”), an aggregate of 6,052,000 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”), of the Company. The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”